The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01766921




Registration number
NCT01766921
Ethics application status
Date submitted
10/01/2013
Date registered
11/01/2013
Date last updated
30/01/2019

Titles & IDs
Public title
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Scientific title
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Secondary ID [1] 0 0
V89_13
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pandemic H5N1 Influenza 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Adjuvanted H5N1 pandemic influenza vaccine

Experimental: aH5N1c - High dose -

Experimental: aH5N1c - Low dose -


Treatment: Other: Adjuvanted H5N1 pandemic influenza vaccine
Comparison of two doses of aH5N1c vaccine

Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers =40 Against A/H5N1 Strain.
Assessment method [1] 0 0
The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers =40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion. The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer =40 meets or exceeds 60%.
Timepoint [1] 0 0
Baseline (day 1) and Three weeks after 2nd vaccination (day 43)
Primary outcome [2] 0 0
The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.
Assessment method [2] 0 0
Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion. Seroconversion is defined as, a postvaccination titer =40 in subjects with a prevaccination HI titer \<10; or in subjects with prevaccination HI titer =10, a minimum four-fold rise in postvaccination HI antibody titer. The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 30%.
Timepoint [2] 0 0
Three weeks after 2nd vaccination (day 43)
Primary outcome [3] 0 0
Number of Subjects Reporting Solicited Local and Systemic Adverse Events, After Any Vaccination.
Assessment method [3] 0 0
Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following vaccination with either low or high dose of aH5N1c vaccine.
Timepoint [3] 0 0
From day 1 through day 7 after any vaccination.
Primary outcome [4] 0 0
Number of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.
Assessment method [4] 0 0
Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with aH5N1c vaccine
Timepoint [4] 0 0
Day 1 through day 387 after any vaccination
Secondary outcome [1] 0 0
Geometric Mean Ratios (GMR) Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.
Assessment method [1] 0 0
Immunogenicity was measured as the GMR. The ratio of postvaccination to prevaccination HI geometric mean titers (GMTs) is reported. The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is \>2.0 for subjects \>60 years of age.
Timepoint [1] 0 0
Day 1; day 22; day 43 and day 387
Secondary outcome [2] 0 0
Percentages Of Subjects With HI Titers =40 Against A/H5N1 Strain
Assessment method [2] 0 0
Immunogenicity was assessed in terms of percentage of subjects achieving HI titers \>40, three weeks after second vaccination with aH5N1c according to the CHMP criterion. The European Licensure (CHMP) criterion is met if the percentage of subjects achieving HI titers =40 is \>60%.
Timepoint [2] 0 0
Day 1, day 22, day 43 and day 387.
Secondary outcome [3] 0 0
The Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain
Assessment method [3] 0 0
Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, three weeks after receiving two injections of either low dose or high dose aH5N1c vaccine according to the CHMP criterion. Seroconversion is defined as a postvaccination titer =40 in subjects with a prevaccination HI titer \<10; or in subjects with prevaccination HI titer =10, a minimum four-fold rise in postvaccination HI antibody titer. The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion is \>30%.
Timepoint [3] 0 0
Day 22, day 43 and day 387

Eligibility
Key inclusion criteria
1. Healthy elderly subjects =65 years,
2. Individuals willing to provide written informed consent,
3. Individuals in good health,
4. Individuals willing to allow for their serum samples to be stored beyond the study period.
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Individuals not able to understand and follow study procedures,
2. History of any significant illness,
3. History of any serious chronic medical condition or progressive disease,
4. Presence of medically significant cancer,
5. Known or suspected impairment/alteration of immune function,
6. Presence of any progressive or severe neurologic disorder,
7. Presence of any bleeding disorders or conditions that prolongs bleeding time,
8. History of allergy to vaccine components,
9. Receipt of any other investigational product within 30 days prior to entry into the study,
10. History of previous H5N1 vaccination,
11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
12. Receipt of any other vaccine within 2 weeks prior to entry into the study
13. Body temperature =38°C.0 (=100.4° F) and/or acute illness within 3 days of intended study vaccination,
14. Body mass index (BMI) = 35 kg/m2,
15. History of drug or alcohol abuse,
16. Any planned surgery during study period,
17. Individuals conducting the study and their immediate family members,
18. Individuals with behavioral or cognitive impairment or psychiatric diseases.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
42 Hunter Clinical Research - Newcastle
Recruitment hospital [2] 0 0
44 Wesley Research Institute Clinical Trials Center - Auchenflower
Recruitment hospital [3] 0 0
40 CMAX - Adelaide
Recruitment hospital [4] 0 0
41 Linear Clinical Research - Nedlands
Recruitment hospital [5] 0 0
45 Childrens Clin Rsrch Facility - Perth
Recruitment postcode(s) [1] 0 0
2292 - Newcastle
Recruitment postcode(s) [2] 0 0
4066 - Auchenflower
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment postcode(s) [5] 0 0
6872 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Utah
Country [8] 0 0
New Zealand
State/province [8] 0 0
Christchurch
Country [9] 0 0
Thailand
State/province [9] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Vaccines
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
Department of Health and Human Services
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis vaccines and Diagnostics
Address 0 0
Novartis Vaccines
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.